产品说明书

OG-L002

Print
Chemical Structure| 1357302-64-7 同义名 : -
CAS号 : 1357302-64-7
货号 : A220151
分子式 : C15H15NO
纯度 : 99%+
分子量 : 225.286
MDL号 : MFCD27997969
存储条件：

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(466.07 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • KDM1

    LSD1, IC50:20 nM
描述 The histone H3K9 demethylase LSD1 plays a critical role in the regulation of herpes simplex virus (HSV) infection. OG-L002 is a selective inhibitor of LSD1 with an IC50 value of 0.02μM. It is also a potent inhibitor of monoamine oxidases (MAO) with IC50 values of 1.38μM and 0.72μM for MAO-A and MAO-B, respectively. OG-L002 inhibited viral immediate-early gene expression in HeLa and HFF cells with IC50 values of ~10µM and ~3µM, respectively. Treatment of Hela cells with 50µM OG-L002 for 24 hours reduced viral yields compared with the DMSO-treated controls. Also in Hela cells, pretreatment with 50µM OG-L002 for 4 hours increased the levels of total histone H3 and H3K9-me2 (20- to 30-fold) associated with viral immediate-early gene promoters. Treatment with OG-L002 (10 - 50µM) for 48 hours repressed viral reactivation in trigeminal ganglia isolated from HSV-infected mice. In BALB/c mice, pretreatment with OG-L002 (6 - 40mg/kg/day) for one week reduced the levels of detectable viral genomes in the ganglia at both 3- and 5-day post-infection. The administration of mice with OG-L002 at a dose of 20mg/kg/day reduced viral genome accumulation at 3-, 5-, and 10-day post-infection[2].
作用机制 OG-L002 is a potent LSD1 inhibitor that blocks HSV lytic replication and reactivation from latency[2].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.44mL

0.89mL

0.44mL

22.19mL

4.44mL

2.22mL

44.39mL

8.88mL

4.44mL
参考文献

[1]Liang Y, Quenelle D, et al. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. MBio. 2013 Feb 5;4(1):e00558-12.

[2]Liang Y, Quenelle D, Vogel JL, Mascaro C, Ortega A, Kristie TM. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. mBio. 2013 Feb 5;4(1):e00558-12